The antimicrobial activities of garenoxacin and eight other antibiotics against 641 anaerobic isolates were evaluated with the NCCLS agar dilution method. Overall, the MICs of garenoxacin for 50 and 90% of the strains tested (in micrograms per milliliter) were as follows: Bacteroides fragilis group, 0.5 and 2; Prevotella spp., 0. 25 Resistance to ␤-lactams, clindamycin, and metronidazole among anaerobes is increasing worldwide (5, 10, 16, 20, 21, 23) . The older quinolones ciprofloxacin and levofloxacin provide only limited activity against many anaerobic species (7, 8, 11, 14, 28, 31) . This deficiency has been addressed in the development of newer quinolones such as moxifloxacin or gatifloxacin with significantly improved antianaerobic activity (2, 4, 8, 11, 26, 31) .
Garenoxacin is a novel orally and parenterally available desfluoro (6) quinolone that lacks a fluorine molecule at the C-6 position. It displays a high degree of in vitro activity against a broad range of gram-positive and gram-negative bacterial pathogens, including anaerobes (6, 12, 13, 15, 17, 24, 25, 29, 30) .
In this study, the antianaerobic activity of garenoxacin was compared to those of antianaerobic reference drugs and three other fluoroquinolones against 641 anaerobic bacteria isolated from human clinical sources (i.e., blood culture, peritonitis, chronic sinusitis and otitis, lung abscess) during the years 2000 and 2001 at the Department of Microbiology, Faculty of Pharmacy, University of Lille, Lille, France, or the Institute of Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Leipzig, Germany. All bacteria were identified in accordance with classical methods (18) , subcultured, and then frozen in Rosenow medium (Bio-Rad, Marnes-la-Coquette, France) or in skim milk (Oxoid, Basingstoke, Hampshire, England) at Ϫ70°C until use. Four American Type Culture Collection (ATCC) control strains suggested by the NCCLS (Bacteroides fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, Clostridium perfringens ATCC 13124, and Eggerthella lenta ATCC 43055) were included with each test run; in every case, results were within the control range.
The following antimicrobial agents were obtained as powders of known potency from their respective manufactures: amoxicillin and clavulanic acid (SmithKline Beecham), imipenem (Merck Sharp & Dohme), clindamycin (Pharmacia), metronidazole (Sigma), ciprofloxacin and moxifloxacin (Bayer), levofloxacin (Aventis), and garenoxacin (Bristol-Myers Squibb).
Agar dilution susceptibility testing was performed in accordance with NCCLS document M11-A5 (22) . Drugs were dissolved as recommended by the manufacturer. Plates contained serial doubling dilutions of each antimicrobial agent. Either clavulanate was added to amoxicillin at a fixed ratio of 1:2 (310 strains tested in Leipzig) as recommended by the NCCLS (22) or MICs were determined in the presence of a fixed clavulanic acid concentration of 2 g/ml (n ϭ 331, tested in Lille), as suggested by the French Committee on Antimicrobial Susceptibility Testing (1). In addition, French isolates were also tested at amoxicillin-clavulanic acid concentrations of 16 and 8, 8 and 4, 4 and 2, and 2 and 1 g/ml, respectively. Reading of the MICs was performed after 48 h of incubation in an anaerobic chamber. If at that time bacterial growth was not sufficient as indicated by the control plates, incubation was continued for up to 5 days altogether. The MIC of an antibiotic for an organism was defined as the lowest concentration of an antimicrobial agent yielding no growth or a marked change in growth compared to that on the control plate.
All of the bacterial strains isolated in Lille were examined for ␤-lactamase production by the nitrocefin disk method.
The distribution of the MICs for the 641 bacterial strains is presented in Tables 1 to 10 . At Յ2 g/ml, garenoxacin inhibited 93% (597 of 641) of the isolates studied and was the most active of the quinolones tested against anaerobes. Among the B. fragilis group isolates, the rate of resistance to clindamycin was 30% in Lille and 13% in Leipzig. All strains of B. fragilis with decreased susceptibility to metronidazole were isolated at the Department of Microbiology in Lille. Almost all of the strains of the B. fragilis group (96.5%) were resistant to amoxicillin. All 130 B. fragilis strains examined in Lille produced ␤-lactamase. Addition of clavulanate enhanced the activity of amoxicillin against ␤-lactamase-producing strains. Resistance to imipenem due to carbapenemase production is still rare. It was found in one strain of B. fragilis from Lille and in one strain of B. thetaiotaomicron from Leipzig. ␤-Lactamase production was detected among 24 (66%) of 35 Prevotella species and 3 (15%) of 20 Fusobacterium species by the nitrocefin test (tested in Lille). ␤-Lactamase production can be assumed for 9 (45%) of 20 Prevotella strains and 9 (45%) of 20 Fusobacterium strains from Leipzig for which the amoxicillin MICs were Ն0.5 g/ml.
Garenoxacin was at least fourfold more potent than moxifloxacin, levofloxacin, or ciprofloxacin against Clostridium spp. Garenoxacin inhibited 36 (78%) of 46 Clostridium difficile strains at a concentration of 4 g/ml and was the most active of the quinolones tested. Interestingly, two strains of C. difficile had decreased susceptibility to metronidazole (MIC, 8 to 16 g/ml). The quinolones were found to be active against all non-spore-forming gram-positive bacilli, except for eight ciprofloxacin-resistant bifidobacteria. All gram-positive anaerobic cocci except two strains were inhibited by garenoxacin at 1 g/ml or less.
The MICs of amoxicillin-clavulanate for 50 and 90% of the strains tested (MIC 50 and MIC 90 , respectively) were similar, irrespective of the test method.
The results of this study show that garenoxacin displays in vitro antianaerobic activity that suggests clinical usefulness. This is in accordance with previous but less extensive investigations. Hoellman et al. (17) have reported a BMS-284756 (garenoxacin) MIC 50 of 0.5 g/ml and an MIC 90 of 2 g/ml for 357 recently isolated anaerobes of human origin. In a study by (29) reported MIC 50 s and MIC 90 s that were 2 to 4 log 2 dilutions lower than ours. These differences may be due to variations in test methods and media and smaller sample sizes.
Unlike some other fluoroquinolones, garenoxacin demon- strated good activity against the B. fragilis group and clostridia other than C. difficile, important pathogens involved in intraabdominal infections and sepsis. Since garenoxacin is also active against most members of the family Enterobacteriaceae (12) and has "moderate to good activity" against enterococci other than vancomycin-resistant enterococci and E. faecium (6, 13, 24) , it may be useful in the treatment of intra-abdominal infections. Garenoxacin seems not to be an option for the treatment of C. difficile-associated diarrhea since 11 of 46 C. difficile isolates were resistant. This is in accordance with the results of Ackermann et al. (3), who indicated an association between moxifloxacin resistance and amino acid substitution in the gyrA gene. Analysis of the MICs of anaerobic isolates from two different countries (France and Germany) did not reveal any appreciable differences (data not shown), with the exception of clindamycin. Clindamycin was significantly less active against B. (5) reported similar results and found that the resistance to clindamycin had increased among members of the B. fragilis group in recent years to 29% (5) and 16% (27) . Betriu et al. (9) and Lubbe et al. (19) identified clindamycin resistance rates of 34 and 29%, respectively. In summary, garenoxacin had the broadest antianaerobic activity among the quinolones tested, inhibiting almost all of the anaerobic bacterial strains tested. Clinical trials to establish the potency of garenoxacin as a therapeutic option are necessary.
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